A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1

Phase 1

• Conditions: Amphetamine-Related Disorders

• Registration Number: NCT00267657
• Lead Sponsor: National Institute on Drug Abuse (NIDA)

Brief Summary

In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.

Detailed Description

In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.

Study Timeline

• Study Start: 2004-01
• Study Completion: 2004-11
• Status Verified: 2005-12
• Study First Submitted: 2005-12-20
• Study First Submitted QC: 2005-12-20
• Study First Posted: 2005-12-21
• Last Update Submitted: 2017-01-10
• Last Update Posted: 2017-01-11

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Please contact site for more details

Exclusion Criteria

• Please contact site for more details

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
CNS norepinephrine turnover
Cardiovascular
Subjective symptoms/Mood Effects
Craving

Trial Locations

Locations (1)

U of CA, San Francisco; 🇺🇸 San Francisco, California, United States